AzTrials
AzTrials

Spondylolisthesis, Lumbar RegionNCT03344484

Midline Versus Paramedian Approaches in Treating Degenerative Lumbar Spondylolisthesis

A study testing Surgical approach in people with Spondylolisthesis, Lumbar Region, run by Nova Scotia Health Authority at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

For the increasing numbers of patients undergoing fusion procedures for the degenerative lumbar spine, infection and re-operation can negatively impact outcomes. Numerous observational and retrospective reviews have shown advantages to para-median versus midline approaches; however, recent systematic reviews have… Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Spondylolisthesis, Lumbar Region
What is being tested?
Surgical approach
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteCanada
Study dates
30 Jan 2018to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • 1) surgical candidates with single or two level degenerative spondylolisthesis with the following clinical findings:
  • a clinical history of back, buttock and leg pain with walking or standing that is improved when lying, sitting or bending forward
  • a clinical history of leg symptoms that are greater than or equal to back symptoms with walking or standing
  • greater than 6 months of symptoms with failed conservative care
  • 2) sufficiently fluent in English to provide informed consent and complete questionnaires with or without the need of an interpreter.

Who cannot join

  • 1) clinical history of osteoporotic fracture or chronic oral steroid use;
  • 2) previous posterior lumbar spinal surgery (excluding prior microdiscectomy); and
  • 3) patients who have evidence of neurological disorders that affect physical function (e.g. peripheral neuropathy), neuromuscular disorders (e.g. multiple sclerosis, Parkinson's etc.) or systemic illness (e.g. inflammatory arthritis) that affects physical function

Trial locations and contacts

1 site in 1 country.

Andrew Glennie, MD contact

902-473-3707

andrew.glennie@nshealth.ca

Canada1 site, 1 recruiting
  • QEII Health Sciences Centre - Halifax Infirmary site

    Halifax, Nova Scotia, B3H3A7

    Orthopaedic Adult Spine Group, 902-473-3707, cynthia.dunningzwicker@nshealth.ca

    Recruiting

Other trials in Canada

About this study

Official title: A Pilot Study Comparing Midline Versus Paramedian Approaches to the Lumbar Spine for Single- or Two-Level Fusions in Degenerative Spondylolisthesis

For the increasing numbers of patients undergoing fusion procedures for the degenerative lumbar spine, infection and re-operation can negatively impact outcomes. Numerous observational and retrospective reviews have shown advantages to para-median versus midline approaches; however, recent systematic reviews have shown a need for a well-powered, prospective randomized control trials comparing both exposures. As a step towards a long-term goal of an RCT to address this issue, the purpose of this pilot study is to gather initial data to examine whether operative approach impacts the short-term infection rate, re-operation rate, length of stay, and overall costs to the system. Patients deemed appropriate surgical candidates with single or two-level degenerative spondylolisthesis will be approached for participation, and randomized into either the midline or paramedian group. Initial follow-ups will be at 2 and 6 weeks, and 3 months. Infection rates, inpatient and outpatient adverse events, re-operation rates, radiation exposure and costs will be determined. Cost effectiveness analysis will be estimated comparing each procedure using a bottom-up estimation. Post-operative wound infection can have a significant effect on patient short and long term outcomes. If a significant difference in infection rate is demonstrated, as well as lower re-operation rates, shorter stays, and decreased overall costs, adoption of paramedian approaches to single or two-level fusions of the lumbar spine might be suggested, providing fuel for a full-scale RCT.

Read the detailed description

Paramedian lumbar interbody fusion has been hypothesized to be advantageous over midline approaches for several reasons, the most important of which is lower post-operative infection rates. To achieve our long-term goal of conducting a RCT to examine this issue in-depth, a pilot study is initially required to examine if this surgical approach may indeed lower infection rates and associated health care cost savings.

It is hypothesized that: (1) there will be a statistically- and clinically-significant difference in infection rates with each approach to the lumbar spine, with those for the paramedian approach being lower; and (2) as a result of lower infection and complication rates, and reduced length of stay, the costs associated with the paramedian approach to the spine will be substantially less.

All consecutive patients deemed appropriate surgical candidates with single or two-level degenerative spondylolisthesis will be approached for participation and inclusion/exclusion criteria will be evaluated. (Note: Target enrollments will not be set a priori, but determined through the course of this proposal.) Once patients are confirmed to be eligible for the study, baseline patient reported outcome data will be collected (ODI, SF-12, EQ-5D, PHQ-9 and generic demographic information). Recruits will be randomized into either the midline or paramedian group using a computer-generated randomization process. After surgery, the surgeon will complete a post-operative summary, discharge form and adverse events form. Follow-up appointments at 6 weeks and 3 months will include repeating the patient reported health outcome questionnaires (ODI, SF-12, EQ-5D, PHQ-D) as well as a cost diary and pain questionnaire. With the assistance of our institution's Research Methods Unit, data analysis will be conducted. Continuous variables (length of stay, SF-12, EQ-5D) will be compared using students T-test while adjusting for potential confounders (diabetes, primary diagnosis, etc) using multi regression models. Categorical data will be analyzed using Chi-squared analysis while controlling for confounders using Cox-proportional hazards ratios.

One of the primary outcomes will be infection rates. To avoid bias in this area, infection will be tracked using the Center for Disease Control (CDC) criteria for diagnosing both deep and superficial infections. Deep infections will be diagnosed with deep wound cultures. The CDC criteria for diagnosing superficial infection is erythema, drainage, dehiscence and "surgeon opinion", allowing for significant subjectively in superficial infections. As such, it is possible that surgeons may preferentially diagnose more midline or Wiltse incisions with superficial infection depending on whether they may have an inherent favoured approach. While it is impossible to truly blind surgeons, allied health care personnel who would have less bias in favour of one approach will assess all wounds. This is in-line with current practice, as wounds are generally assessed by nurses in the clinic, and staples or sutures are removed at the two-week follow-up visit. Surgeons are only asked to assess wounds that are questionable. This would decrease some of the potential bias as part of this un-blinded study. Surgeon opinion will have no impact on deep infection, because this will generally require irrigation and debridement in the operating theater which will be captured.

The benefits, in the event of a positive study outcome, will lead to substantial improvements in patient care with reduced infection rates. If the evidence is compelling from a pilot study, the goal would be to move to a prospective, multi-centered randomized control trial to further examine this research question and potential adoption of more midline sparing surgery for fusion procedures of the lumbar spine. In the event that significant cost savings are demonstrated, quality assurance officers and policy makers would be compelled to adjust remuneration codes and possibly limit the compensation in cases where a midline approach was chosen. The cost savings for the system would be substantial even if only a significant difference in infection rate was demonstrated. There are risks are for lumbar spine surgery in general. At present, these risks are assumed to be equivalent with the two surgical approaches to be examined in this study and patients joining in the study can be assured of high-quality care for their condition regardless of the treatment arm to which they are allocated. However, if this proposed study can show that infection rates can be lowered with surgical approach, then the benefits definitely outweigh the risks.

Being tested
Surgical approach
Medical subject headings
Spondylolisthesis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Surgical approachOther

    Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion

Study groups in NCT03344484
Study groupRoleWhat they receive
Midline ApproachExperimentalA midline surgical approach will be used for the exposure required to complete the lumbar fusion.
Receives: Other: Surgical approach
Paramedian ApproachExperimentalA paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
Receives: Other: Surgical approach

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Infection rate

    infection will be tracked using the Center for Disease Control (CDC) criteria for diagnosing both deep and superficial infections. Deep infections will be diagnosed with deep wound cultures. The CDC criteria for diagnosing superficial infection is erythema, drainage, dehiscence and "surgeon opinion", allowing for significant subjectively in superficial infections.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Nov 2017
  2. Study start30 Jan 2018
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03344484
Sponsor's protocol ID
REB1022987
Status last verified
Aug 2024
First submitted
13 Nov 2017
Last updated
21 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Surgical approach in people with Spondylolisthesis, Lumbar Region, run by Nova Scotia Health Authority at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Andrew Glennie, MD (902-473-3707, andrew.glennie@nshealth.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Infection rate (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in